Stockreport

Poplar Therapeutics Closes $45 million Series A Extension to Advance Development of Lead Program, PHB-050, A New Class of Anti-IgE Therapy for Multiple Atopic Conditions [Yahoo! Finance]

Janus Henderson Group plc Ordinary Shares  (JHG) 
Last janus henderson group plc ordinary shares earnings: 4/30 04:00 am Check Earnings Report
US:NYSE Investor Relations: snl.com/irw/corporateprofile/4147331
PDF Proceeds will support further clinical development of lead program PHB-050 in food allergy and other atopic conditions Phase 1 clinical trial for PHB-050 remains on t [Read more]